Acetate
- Generic Name
- Acetate
- Drug Type
- Small Molecule
- Chemical Formula
- C2H3O2
- CAS Number
- 71-50-1
- Unique Ingredient Identifier
- 569DQM74SC
Pfizer to Showcase Breakthrough Cancer Therapies at ASCO 2025 with Over 60 Presentations
• Pfizer will present data from more than 60 abstracts at ASCO 2025, including 15 oral presentations highlighting advancements across breast, genitourinary, hematologic, thoracic, and colorectal cancers.
• Two late-breaking presentations will be featured in ASCO's press program, including pivotal survival data for BRAFTOVI in colorectal cancer and progression-free survival results for vepdegestrant in metastatic breast cancer.
• The company will showcase novel antibody-drug conjugate combinations with immunotherapy and present five-year survival data for XTANDI in prostate cancer, supporting Pfizer's goal of delivering eight breakthrough cancer medicines by 2030.
Pathos AI Initiates Phase 1b/2a Trial of Pocenbrodib for Metastatic Castration-Resistant Prostate Cancer
• Pathos AI has dosed the first patient in a Phase 1b/2a trial evaluating pocenbrodib, a CBP/p300 inhibitor, alone and in combination with established therapies for metastatic castration-resistant prostate cancer.
• The multicenter trial will enroll approximately 203 patients who have progressed despite prior therapy, with primary objectives to assess safety, response rates, and determine recommended Phase 2 dosing.
• Pocenbrodib targets underlying resistance mechanisms to AR-targeted therapy through CBP/p300 inhibition, addressing a significant unmet need in advanced prostate cancer treatment.
TALAPRO-2 Trial: Talazoparib-Enzalutamide Combo Shows Significant Survival Benefit in Metastatic Prostate Cancer
• The combination of talazoparib and enzalutamide demonstrated an 8.8-month improvement in overall survival compared to enzalutamide alone in metastatic castration-resistant prostate cancer patients.
• Patients with homologous recombination repair-deficient tumors showed an even more pronounced benefit, with a 14-month survival improvement and 38% reduction in death risk.
• The phase 3 TALAPRO-2 trial revealed manageable safety profiles with no new concerns, despite grade 3/4 anemia occurring in 49% of patients, which was effectively managed through dose adjustments.
Verastem's Avutometinib and Defactinib Combination Receives FDA Priority Review for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
• The FDA has granted Priority Review to Verastem Oncology's NDA for avutometinib combined with defactinib for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).
• The PDUFA target action date is set for June 30, 2025, with the FDA indicating that an advisory committee meeting is not currently planned.
• The NDA is supported by Phase 2 RAMP 201 trial data, demonstrating substantial overall response rates and durable responses in patients with recurrent KRAS mutant LGSOC.
• If approved, this combination therapy would be the first FDA-approved treatment specifically for adults with recurrent KRAS mutant LGSOC, addressing a significant unmet need.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath